Susquehanna International Group, LLP Apellis Pharmaceuticals, Inc. Put Options Transaction History

Susquehanna International Group, LLP

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$28.84 - $41.15 $1.79 Million - $2.56 Million	-62,100 Reduced 22.59%	212,800 $6.14 Million
Q2 2024 Aug 15, 2024	SELL	$38.07 - $59.71 $2.14 Million - $3.36 Million	-56,200 Reduced 16.97%	274,900 $10.5 Million
Q1 2024 May 07, 2024	SELL	$55.39 - $72.47 $3.11 Million - $4.07 Million	-56,100 Reduced 14.49%	331,100 $19.5 Million
Q4 2023 Feb 14, 2024	SELL	$37.14 - $64.82 $315,690 - $550,970	-8,500 Reduced 2.15%	387,200 $23.2 Million
Q3 2023 Nov 14, 2023	BUY	$23.65 - $89.22 $3.95 Million - $14.9 Million	166,900 Added 72.95%	395,700 $15.1 Million
Q2 2023 Aug 11, 2023	SELL	$76.68 - $93.31 $8.25 Million - $10 Million	-107,600 Reduced 31.99%	228,800 $20.8 Million
Q1 2023 May 16, 2023	BUY	$46.59 - $66.96 $5.47 Million - $7.86 Million	117,400 Added 53.61%	336,400 $22.2 Million
Q4 2022 Feb 14, 2023	BUY	$43.24 - $61.04 $2.88 Million - $4.06 Million	66,500 Added 43.61%	219,000 $11.3 Million
Q3 2022 Nov 14, 2022	BUY	$44.76 - $69.66 $3.63 Million - $5.64 Million	81,000 Added 113.29%	152,500 $10.4 Million

308

115M

3.85M

1.09M

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.64B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.